Quick Answer
Edesa Biotech, Inc. reported Cash and Equivalents of $7.09 million for fiscal year 2022.
Edesa Biotech, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $7.09M | -9.5% |
| 2021 | $7.84M | +8.7% |
| 2020 | $7.21M | +43.4% |
| 2019 | $5.03M | +49.4% |
| 2018 | $3.37M | -20.3% |
| 2018 | $4.23M | -7.6% |
| 2017 | $4.57M | -38.4% |
| 2016 | $7.42M | +87.5% |
| 2015 | $3.96M | -54.9% |
| 2014 | $8.77M | +4.1% |
| 2014 | $8.42M | +7.2% |
| 2013 | $7.86M | +686.8% |
| 2012 | $999.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2023 | $6.46M | -49.6% | -13.6% |
| March 31, 2023 | $7.47M | -53.0% | -9.7% |
| December 31, 2022 | $8.27M | +40.6% | +16.6% |
| September 30, 2022 | $7.09M | -9.5% | -44.6% |
| June 30, 2022 | $12.81M | +59.1% | -19.4% |
| March 31, 2022 | $15.89M | +44.9% | +170.2% |
| December 31, 2021 | $5.88M | -6.7% | -25.0% |
| September 30, 2021 | $7.84M | +8.7% | -2.6% |
- Edesa Biotech, Inc. showed a decrease of -9.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2022 period, Edesa Biotech, Inc.’s cash and equivalents has grown by 609.8% (from $999.0 thousand to $7.09 million).
- The most recent figure is from Edesa Biotech, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on December 16, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: